Syphilis Immunoassay Diagnostics Market

Syphilis Immunoassay Diagnostics Market Research, 2031

The global syphilis immunoassay diagnostics market was valued at $315.5 million in 2021, and is projected to reach $446.0 million by 2031, growing at a CAGR of 3.5% from 2022 to 2031. Syphilis is a serious bacterial infection that can affect both men and women. It is also seen in HIV-positive patients. Syphilis has several clinical manifestations, making laboratory testing a very important aspect of diagnosis. Syphilis diagnosis must always rely on a high level of clinical suspicion and routine screening for high-risk patients. The recent availability of faster, automated treponemal testing has resulted in a reversal of the normal syphilis screening strategy. 

The COVID-19 pandemic affected the syphilis immunoassay diagnostics industry in a negative way just as various other diagnostics and biotechnology industries were affected. The COVID-19 pandemic has disrupted virtually each aspect of healthcare provision including syphilis diagnostics. The report of Centers for Disease Control and Prevention (CDC) released in April 2022 shows that the reported cases of sexually transmitted diseases (STDs) declined during the first few months of the pandemic, which the CDC agency attributes to a drop in testing services. It is because the healthcare facilities were overwhelmed with COVID-19 patients, and other facilities were made to temporarily shut their doors and there were only fewer places for individuals to turn for STD screening. Moreover, according to the data by CDC, around 30% decrease in total number of positive STD test results were recorded through electronic laboratory reporting (ELR) and 40% drop in positive tests via paper reporting were recorded in the year 2020 as compared to the data of year 2019. Particularly, around 38% decrease in positive reactive syphilis serologies were recorded through electronic laboratory reporting and 49% via paper reporting in 2020. Moreover, outbreak of Coronavirus disease (COVID-19) has acted as a significant restraint on the syphilis immunoassay diagnostics market in COVID-19 pandemic as supply chains were disrupted due to restrictions on trade of diagnostics products across countries. In addition, COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the syphilis immunoassay diagnostics market. Pandemic has directly affected the supply of syphilis immunoassay diagnostics products to syphilis testing firms. Moreover, the spread of coronavirus has reduced syphilis testing organizations’ willingness and ability to access the syphilis testing technologies. COVID-19’s interference with the research and development of new test products was one of the most significant blows that has been dealt to the syphilis immunoassay diagnostics market. Overall, the COVID-19 pandemic had a negative impact on the syphilis immunoassay diagnostics industry owing to the decrease in the reported cases of sexually transmitted diseases (STDs) during the first few months of the pandemic. In addition, supply chains were disrupted due to restrictions on trade of diagnostics products across countries which impacted the growth of the market.

Blood tests can be used to diagnose syphilis. These tests can prove the presence of antibodies produced by the body to combat infections. As these antibodies reside in the body for years, the test can be used to establish whether an infection is current or old. Antibiotics are used to treat it, especially in the early stages.

The growth of the Syphilis Immunoassay Diagnostics Market Size is driven by rising in socioeconomic factors such as sexually transmitted diseases and an increase in the proportion of sex under the influence of numerous drugs such as heroin, cocaine, methamphetamine, cannabis, benzodiazepines, and alcohol. Moreover, the increase in rates of fatal syphilis infections, the surge in testing facilities, the widespread use of technology in testing, and the availability of on-the-spot testing help in the Syphilis Immunoassay Diagnostics Market Growth. For instance, according to the data from World Health Organization (WHO), there were an estimated 374 million new infections with 1 of 4 STIs such as chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million) in 2020. However, a lack of knowledge among individuals in emerging economies is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies and advancements in the Syphilis Immunoassay Diagnostics Industry drives the Syphilis Immunoassay Diagnostics Market Size.

The global syphilis immunoassay diagnostics market is segmented based on product type, technology, end-user, and region. As per product type, the market is bifurcated into analyzers and kits & reagents. According to technology, it is classified into CLIA and ELISA. Depending on the end user, it is classified into blood banks, diagnostic labs, and hospitals. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The syphilis immunoassay diagnostics market is segmented into Product Type, Technology, and End User.

By product type, the market is classified into analyzers and kits & reagents. The kits and reagents segment is projected to exhibit the fastest market growth during the forecast period, owing to an increase in the prevalence of syphilis among the population, an increase in healthcare expenditure, and a rise in the adoption of syphilis diagnostic products for screening of the diseases. The syphilis diagnostic kits and reagents detect the presence of antibodies IgG and IgM to Treponema Pallidum (TP) in (whole blood), serum, or plasma samples to aid in the diagnosis of Syphilis. The increase in the prevalence of syphilis may trigger diagnostic procedures thereby increasing the adoption of diagnostic kits and reagents.

By technology, the market is classified into CLIA and ELISA. The CLIA segment is anticipated to have largest Syphilis Immunoassay Diagnostics Market Share for the Syphilis Immunoassay Diagnostics Market Forecast period, owing to an upsurge in the number of patients of sexually transmitted diseases, an increase in the number of syphilis diagnosis procedures, and a rise in the number of research and development activities for syphilis testing. CLIA can be employed for screening syphilis in blood donors for its good sensitivity, ease of automation and short turn-around-time. Hence, the increased adoption of this technology in the screening can help the growth of the market. Moreover, the surge in testing facilities, the widespread use of technology in testing, and the availability of on-the-spot testing help in the growth of the market.

By end user, the market is classified into blood banks, diagnostic labs, and hospitals. The blood banks segment is anticipated to have the largest Syphilis Immunoassay Diagnostics Market Share, owing to an increase the in the number of biotechnology companies, growth in the Syphilis Immunoassay Diagnostics Industry, and a rise in research activities of cell therapy. Moreover, the surge the in the number of pharmaceutical companies further contributed to the growth of the market. The U.S. Food and Drug Administration (FDA) recommends that donation facilities are required to perform a serological screening test on each donation of blood for the presence of syphilis. The donors must be tested upon their first plasmapheresis and then every four months thereafter as they do not fail the first test in the blood banks.

In 2021, North America was the dominant region and is expected to remain dominant during the forecast period, owing to high prevalence rate of syphilis, an increase the in the number of market players, and a surge in testing facilities in the region. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, owing to the presence of high populace countries, such as India and China, which in turn increases the prevalence rate of sexually transmitted disease and the increasing number of strategies and trends adopted by the market players.

The list of key players profiled are Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc, Danaher Corporation, DiaSorin Group, F. Hoffmann-La Roche AG, Quidel Corporation, Siemens AG and Shenzhen New Industries Biomedical Engineering Co., Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the syphilis immunoassay diagnostics market analysis from 2021 to 2031 to identify the prevailing Syphilis Immunoassay Diagnostics Market Opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the syphilis immunoassay diagnostics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global syphilis immunoassay diagnostics market trends, key players, market segments, application areas, and market growth strategies.

 Syphilis Immunoassay Diagnostics Market Report Highlights